Georg Heß

13.9k total citations · 4 hit papers
192 papers, 6.6k citations indexed

About

Georg Heß is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Georg Heß has authored 192 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Pathology and Forensic Medicine, 62 papers in Oncology and 55 papers in Genetics. Recurrent topics in Georg Heß's work include Lymphoma Diagnosis and Treatment (93 papers), Chronic Lymphocytic Leukemia Research (54 papers) and Hepatitis B Virus Studies (33 papers). Georg Heß is often cited by papers focused on Lymphoma Diagnosis and Treatment (93 papers), Chronic Lymphocytic Leukemia Research (54 papers) and Hepatitis B Virus Studies (33 papers). Georg Heß collaborates with scholars based in Germany, United States and Italy. Georg Heß's co-authors include Dietmar Zdunek, Andreas Viardot, Ralf C. Bargou, Hugo A. Katus, Kerstin Kurz, Evangelos Giannitsis, Martin Schüler, Alfred M. Engel, Bertrand Coiffier and Karl‐Hermann Meyer zum Büschenfelde and has published in prestigious journals such as Science, New England Journal of Medicine and The Lancet.

In The Last Decade

Georg Heß

186 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

2008 798 citations Georg Heß et al. profile →
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

2009 485 citations Georg Heß, Gregor Verhoef et al. Journal of Clinical Oncology profile →
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

2015 386 citations Owen A. O’Connor, Steven M. Horwitz et al. Journal of Clinical Oncology profile →
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

2016 280 citations Georg Heß et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Georg Heß Germany	39	2.2k	2.1k	1.4k	1.4k	1.2k	192	6.6k
Giovanni Barillari Italy	35	2.0k 0.9×	1000 0.5×	1.2k 0.8×	373 0.3×	1.1k 0.9×	141	6.0k
Luca Mazzucchelli Switzerland	46	4.8k 2.1×	2.5k 1.2×	827 0.6×	579 0.4×	1.8k 1.5×	179	10.8k
Frédéric Houssiau Belgium	41	1.2k 0.6×	993 0.5×	558 0.4×	385 0.3×	3.6k 3.0×	149	7.8k
Alessandro Pulsoni Italy	30	1.9k 0.9×	2.1k 1.0×	602 0.4×	1.2k 0.9×	524 0.4×	143	4.5k
Renato Fanin Italy	42	2.0k 0.9×	1.3k 0.6×	665 0.5×	1.4k 1.1×	1.2k 1.0×	226	6.6k
Bruno Varet France	37	1.4k 0.6×	1.1k 0.5×	554 0.4×	2.6k 1.9×	1.4k 1.2×	145	7.6k
Carlos E. Bacchi Brazil	37	2.2k 1.0×	1.6k 0.8×	960 0.7×	350 0.3×	418 0.3×	236	5.7k
Hans Tesch Germany	49	5.3k 2.4×	2.8k 1.3×	395 0.3×	985 0.7×	1.8k 1.5×	346	9.5k
Joachim R. Kalden Germany	44	1.2k 0.5×	829 0.4×	721 0.5×	963 0.7×	5.6k 4.6×	103	11.7k
Won Seog Kim South Korea	48	6.3k 2.8×	7.1k 3.4×	653 0.5×	1.8k 1.3×	3.0k 2.4×	462	10.8k

Countries citing papers authored by Georg Heß

Since Specialization

Citations

This map shows the geographic impact of Georg Heß's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Georg Heß with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Georg Heß more than expected).

Fields of papers citing papers by Georg Heß

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Georg Heß. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Georg Heß. The network helps show where Georg Heß may publish in the future.

Co-authorship network of co-authors of Georg Heß

This figure shows the co-authorship network connecting the top 25 collaborators of Georg Heß. A scholar is included among the top collaborators of Georg Heß based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Georg Heß. Georg Heß is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Singer, Susanne, et al.. (2024). „Patient-reported outcomes“ in medizinischen Registern. PUBLISSO (German National Library of Medicine). 30(4). 304–311.

Schmidt, Christian, Marek Trněný, Eva Giné, et al.. (2024). Trials in Progress: Carman - an International, Randomized Phase II Study Evaluating Early Treatment Intensification in Patients with High Risk Mantle Cell Lymphoma Using CAR-T-Cell Treatment after an Abbreviated Induction Therapy with Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) As Compared to Standard of Care Induction and Maintenance (Arm B). Blood. 144(Supplement 1). 4422.3–4422.3. 2 indexed citations

Bartlett, Nancy L., Laurie H. Sehn, Sarit Assouline, et al.. (2024). Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II. Blood. 144(Supplement 1). 1645–1645. 4 indexed citations

Rejeski, Kai, Yucai Wang, Omar Albanyan, et al.. (2023). The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. American Journal of Hematology. 98(11). 1699–1710. 17 indexed citations

Matasar, Matthew J., Nancy L. Bartlett, Mazyar Shadman, et al.. (2023). Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial. Clinical Lymphoma Myeloma & Leukemia. 24(4). 240–253. 10 indexed citations

Nowakowski, Grzegorz S., Dok Hyun Yoon, Anthea Peters, et al.. (2022). Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. Clinical Cancer Research. 28(18). 4003–4017. 16 indexed citations

Theobald, Matthias, et al.. (2022). Struggling with extensive informed consent procedures for cancer trials—is there even a benefit for the patients?. Supportive Care in Cancer. 30(8). 6593–6602. 1 indexed citations

Moehler, Markus, et al.. (2021). Any progress in informed consenting for cancer treatment? Results from a cross sectional analysis at a comprehensive cancer center. Journal of Cancer Research and Clinical Oncology. 147(7). 2117–2126. 6 indexed citations

Rule, Simon, Martin Dreyling, André Goy, et al.. (2019). Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up. Blood. 134(Supplement_1). 1538–1538. 16 indexed citations

10.

O’Brien, Susan, Peter Hillmen, Steven Coutré, et al.. (2018). Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 18(10). 648–657.e15. 63 indexed citations

11.

Heß, Georg, Simon Rule, Wojciech Jurczak, et al.. (2017). Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus. Leukemia & lymphoma. 58(12). 2824–2832. 15 indexed citations

12.

Dreyling, Martin, Igor Aurer, Sergio Cortelazzo, et al.. (2017). Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. Leukemia & lymphoma. 59(8). 1814–1828. 18 indexed citations

13.

O’Connor, Owen A., Steven M. Horwitz, Tamás Masszi, et al.. (2015). Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. Journal of Clinical Oncology. 33(23). 2492–2499. 386 indexed citations breakdown →

14.

Fayad, Luis, Fritz Offner, Mitchell R. Smith, et al.. (2013). Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab. Journal of Clinical Oncology. 31(5). 573–583. 119 indexed citations

15.

Wierda, William G., Thomas J. Kipps, Jan Dürig, et al.. (2011). Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 117(24). 6450–6458. 86 indexed citations

16.

Dinh, Wilfried, Reiner Füth, Mark Lankisch, et al.. (2011). Fator de diferenciação de crescimento 15: um novo biomarcador em pacientes com disfunção diastólica?. LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas). 28 indexed citations

17.

Norozi, Kambiz, et al.. (2008). Intravenous luteinizing hormone‐releasing hormone has no effect on serum N‐terminal pro‐brain natriuretic peptide in children and adolescents. Pediatrics International. 51(2). 283–288. 4 indexed citations

18.

Williams, Carolyn, Donna Klinzman, Traci E. Yamashita, et al.. (2004). Persistent GB Virus C Infection and Survival in HIV-Infected Men. New England Journal of Medicine. 350(10). 981–990. 196 indexed citations

19.

Meuer, Stefan, Ulrich Moebius, Michael Manns, et al.. (1988). Clonal analysis of human T lymphocytes infiltrating the liver in chronic active hepatitis B and primary biliary cirrhosis. European Journal of Immunology. 18(9). 1447–1452. 60 indexed citations

20.

Kh, Meyer zum Büschenfelde, Walter Arnold, J. Knolle, & Georg Heß. (1976). [Immune response to HBsAg, HBcAg and e-antigen in patients with acute hepatitis and HBsAg carriers with and without liver diseases].. PubMed. 14(3). 365–77. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact